Letter
Author: Fleming, Shaun ; Wei, Andrew H ; Porkka, Kimmo ; Kontro, Mika ; Han, May ; Sun, Haiying ; White, Roisin ; Zhang, Na ; Steensma, David P ; Garcia-Manero, Guillermo ; Narayan, Rupa ; Knapper, Steve ; Naidu, Purushotham ; Sabatos-Peyton, Catherine A ; Tovar, Natalia ; Traer, Elie ; Esteve, Jordi ; Ottmann, Oliver G ; Vey, Norbert ; Wermke, Martin ; Scholl, Sebastian ; Rinne, Mikael L ; Mohammed, Anisa ; Borate, Uma M ; Brunner, Andrew M ; Janssen, Jeroen J W M ; Loo, Sun
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.